The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that the coronavirus (COVID–19) vaccine developed by Novavax, Nuvaxovid, has received regulatory approval, becoming the fifth coronavirus vaccine to be authorised by the MHRA. Nuvaxovid has been approved for use in people aged over 18 for a first and second dose.